ebselen has been researched along with nirmatrelvir in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dou, X; Guo, Z; Huo, T; Jiao, N; Lai, L; Liu, Y; Liu, Z; Lu, Y; Song, S; Su, L; Sun, Q; Wang, B; Wang, C; Xu, G; Yu, Z; Zhang, C; Zhang, L; Zhao, X | 1 |
| Cheng, Y; Claff, T; Gao, S; Gütschow, M; Jing, L; Kang, D; Liu, X; Müller, CE; Schäkel, L; Song, L; Sträter, N; Sylvester, K; Tavis, J; Tollefson, AE; Toth, K; Weiße, RH; Woodson, M; Yang, M; Ye, B; Zhan, P; Zhang, T | 1 |
| Chen, N; Hao, H; Lai, M; Li, Z; Liao, Y; Wan, N; Wu, N; Xiao, Y; Yan, H; Ye, H; Yu, W; Zhao, Y | 1 |
3 other study(ies) available for ebselen and nirmatrelvir
| Article | Year |
|---|---|
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Discovery; Furans; Humans; Hydrazines; Molecular Docking Simulation; Protease Inhibitors; SARS-CoV-2 | 2022 |
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Piperazines; Protease Inhibitors; SARS-CoV-2; Viral Nonstructural Proteins | 2022 |
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
Topics: Animals; Antiviral Agents; COVID-19; Cysteine Endopeptidases; Mice; Molecular Docking Simulation; Papain; Peptide Hydrolases; Protease Inhibitors; Rats; SARS-CoV-2; Viral Nonstructural Proteins; Viral Proteases | 2022 |